Metastatic appendicular soft tissue sarcoma treatment and survival outcomes of 2,553 patients from the SEER database

被引:0
|
作者
Gonzalez, Marcos R. [1 ]
Rizk, Paul [2 ]
Hodo, Thomas W. [3 ]
Bedi, Angad [1 ,4 ]
Karczewski, Daniel [1 ]
Lozano-Calderon, Santiago A. [1 ,5 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Div Orthopaed Oncol, Boston, MA 02144 USA
[2] Univ Florida, Dept Orthopaed Surg, Gainesville, FL 32608 USA
[3] Tulane Univ, Sch Med, Dept Orthopaed Surg, New Orleans, LA 70112 USA
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Orthopaed Surg, Groningen, Netherlands
[5] Massachusetts Gen Hosp, Dept Orthopaed Surg, Div Orthopaed Oncol, Boston, MA 02144 USA
关键词
Soft tissue sarcoma; metastasis; treatment; survival; RHABDOMYOSARCOMA; SURGERY; BREAST; AGE;
D O I
10.20517/2394-4722.2022.138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Patients with soft tissue sarcoma (STS) that present with metastasis at diagnosis have a dire prognosis. Within this patient population, we sought to assess: (1) demographic and clinical characteristics, (2) metastatic patterns, (3) treatment strategies, and (4) disease-specific survival (DSS).Materials and Methods: The SEER database was queried to identify patients with histologically confirmed STS of the pelvis or extremity. Univariate and multivariate analysis was performed using the Cox proportional hazards model. Disease-specific survival (DSS) was analyzed using the Kaplan-Meier method.Results: A total of 22,683 patients were retrieved, out of which 2,553 (11.3%) had metastasis at diagnosis. Leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), liposarcoma, synovial sarcoma, spindle cell sarcoma, and alveolar rhabdomyosarcoma (A-RMS) were the six most common STS presenting with metastasis. Among patients with metastasis, 53.7% and 33.2% of patients had primary tumors located in the lower limb and pelvis, respectively. Lung was the most common site of metastasis in all subtypes except A-RMS, in which bone metastases and lymph node (LN) predominated (85.2% and 62.1%, respectively). Chemotherapy and radiotherapy were associated with higher DSS (HR = 0.788 and HR = 0.755, respectively). Five-year DSS was below 20% in all tumor histologies. Two-year DSS for patients with synchronous lung and liver metastases was 28%.Conclusion: Although the lung was the most common site of metastasis, metastatic patterns are highly variable depending on tumor histology. Metastatic A-RMS is most commonly presented with regional LN and bone involvement. Disease-specific survival remained poor for patients with metastatic disease at presentation regardless of (neo)-adjuvant radiotherapy or chemotherapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Demographic and clinical profile of 1106 adult soft tissue sarcoma patients: A single institutional prospective database experience from India
    Sharma, Jyoti
    Deo, Surya V. S.
    Kumar, Sunil
    Bhoriwal, Sandeep
    Kar, Madhabananda
    Barwad, Adarsh W.
    Thulkar, Sanjay
    Bakhshi, Sameer
    Sharma, D. N.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (03) : 386 - 394
  • [42] Superficial soft tissue sarcomas (S-STS): A study of 367 patients from the French Sarcoma Group (FSG) database
    Salas, Sebastien
    Stoeckle, Eberhard
    Collin, Francoise
    Bui, Binh
    Terrier, Philippe
    Guillou, Louis
    Trassard, Martine
    Ranchere-Vince, Dominique
    Gregoire, Fleur
    Coindre, Jean-Michel
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (12) : 2091 - 2102
  • [43] Multimodal treatment based on thyroidectomy improves survival in patients with metastatic anaplastic thyroid carcinoma: a SEER analysis from 1998 to 2015
    Song, Tao
    Chen, Long
    Zhang, Haibo
    Lu, Yanwei
    Yu, Kun
    Zhan, Wenming
    Fang, Min
    GLAND SURGERY, 2020, 9 (05) : 1205 - +
  • [44] Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study
    Gelderblom, H.
    Blay, J. Y.
    Seddon, B. M.
    Leahy, M.
    Ray-Coquard, I.
    Sleijfer, S.
    Kerst, J. M.
    Rutkowski, P.
    Bauer, S.
    Ouali, M.
    Marreaud, S.
    van der Straaten, R. J. H. M.
    Guchelaar, H-J
    Weitman, S. D.
    Hogendoorn, P. C. W.
    Hohenberger, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 388 - 396
  • [45] Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Bradley, Julie A.
    Kayton, Mark L.
    Chi, Yueh-Yun
    Hawkins, Douglas S.
    Tian, Jing
    Breneman, John
    Wolden, Suzanne L.
    Walterhouse, David
    Rodeberg, David A.
    Donaldson, Sarah S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (01): : 19 - 27
  • [46] Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
    Kaufman, Peter A.
    Brufsky, Adam M.
    Mayer, Musa
    Rugo, Hope S.
    Tripathy, Debu
    Yood, Marianne Ulcickas
    Feng, Shibao
    Wang, Lisa I.
    Quah, Cheng S.
    Yardley, Denise A.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (03) : 875 - 883
  • [47] Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population
    Huang, Pei-Wei
    Chou, Wen-Chi
    Shen, Wen-Chi
    Hung, Chia-Yen
    Huang, Kuan-Gen
    Su, Yu-Li
    Lu, Chang-Hsien
    Liu, Chien-Ting
    Chang, Yueh-Shih
    Liau, Chi-Ting
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (04) : 353 - 360
  • [48] Hearing function in soft tissue sarcoma patients after treatment with carboplatin:: A report from the Late Effects Surveillance System
    Stöhr, W
    Langer, T
    Kremers, A
    Brecht, I
    Treuner, J
    Dinnesen, A
    Beck, JD
    ONCOLOGY REPORTS, 2004, 12 (04) : 767 - 771
  • [49] Treatment Efficiency, Outcome and Surgical Treatment Problems in Patients Suffering From Localized Embryonal Bladder/Prostate Rhabdomyosarcoma: A Report From the Cooperative Soft Tissue Sarcoma Trial CWS-96
    Seitz, Guido
    Dantonello, Tobias M.
    Int-Veen, Christoph
    Blumenstock, Gunnar
    Godzinski, Jan
    Klingebiel, Thomas
    Schuck, Andreas
    Leuschner, Ivo
    Koscielniak, Ewa
    Fuchs, Joerg
    PEDIATRIC BLOOD & CANCER, 2011, 56 (05) : 718 - 724
  • [50] Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846
    Liu, Xinyue
    Xu, Jin
    Li, Feng
    Liao, Zhichao
    Ren, Zhiwu
    Zhu, Lei
    Shi, Yehui
    Zhao, Gang
    Bai, Xu
    Zhao, Jun
    Xing, Ruwei
    Teng, Sheng
    Yang, Yun
    Yang, Jilong
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 122